Atropine Ophthalmic Composition pH Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current ophthalmic atropine compositions face challenges with stability and pH compatibility for low-dose applications, often requiring preservatives that can cause adverse effects, and have limited shelf life due to hydrolysis issues at neutral or basic pH conditions.
Innovation Solution
Development of a stable, preservative-free ophthalmic atropine composition with a pH between 5.0 and 6.0, using a low-strength buffer system, tonicity agents, and viscosity modifiers like hydroxyethyl cellulose, which maintains atropine stability and reduces tropic acid formation to less than 0.35% after two months at 25°C and 60% relative humidity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If atropine is formulated at low concentrations (0.01-0.05% w/v) for pediatric myopia treatment, then side effects like photophobia are reduced, but stability deteriorates due to accelerated hydrolysis to tropic acid
Solution Approach 1:
The patent changes the pH parameter of the formulation to a higher range (pH 6.5-7.5) compared to conventional acidic formulations, which reduces atropine hydrolysis and improves stability while maintaining low concentration (0.01-0.05% w/v) to minimize side effects. This parameter change resolves the contradiction by creating a formulation environment that protects atropine from degradation.
Solution Approach 2:
The patent introduces buffer systems as intermediary substances to maintain the pH within the optimal range of 6.5-7.5. These buffers act as mediators that prevent pH fluctuations which would otherwise accelerate hydrolysis, thereby stabilizing atropine without requiring higher concentrations or acidic conditions.
2Object-affected harmful factors
If ophthalmic solutions are formulated at pH closer to neutral (7.4) to match lacrimal fluid, then physiological compatibility is improved, but atropine stability deteriorates due to accelerated hydrolysis
Solution Approach 1:
The patent optimizes the pH parameter to a specific range (6.5-7.5) that balances physiological compatibility with atropine stability. This refined parameter setting avoids the extreme acidity of conventional formulations while not fully reaching neutral pH, thereby achieving both goals simultaneously through precise parameter control.
Solution Approach 2:
The patent applies local quality by creating a microenvironment within the formulation that maintains optimal pH conditions specifically for atropine stability, while the overall formulation remains physiologically compatible. The buffer system creates localized pH control that protects atropine without compromising overall biocompatibility.
3Stability of the object's composition
If conventional acidic pH formulations (pH ≤4) are used for atropine, then stability is improved, but physiological suitability for ophthalmic use deteriorates
Solution Approach 1:
The patent fundamentally changes the pH parameter from the conventional acidic range (≤4) to a near-physiological range (6.5-7.5). This parameter transformation eliminates the need for acidic conditions to achieve stability, allowing the formulation to be both stable and physiologically suitable for ocular administration.
Solution Approach 2:
The patent inverts the conventional approach by rejecting the traditional acidic pH formulation strategy. Instead of accepting acidity as necessary for stability, the patent demonstrates that stability can be achieved through higher pH combined with low atropine concentrations, effectively inverting the established formulation paradigm.
4Reliability
If preservatives like benzalkonium chloride are added to multi-dose atropine formulations, then microbial stability is improved, but ocular tissue damage occurs
Solution Approach 1:
The patent extracts and eliminates preservatives from the formulation entirely. By removing this harmful component, the patent achieves a preservative-free formulation that relies on optimized pH and low atropine concentration to maintain stability, thereby preventing ocular tissue damage while still ensuring microbial safety through proper formulation design.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition achieves significant stability and safety by minimizing tropic acid formation and avoiding preservative-related side effects, allowing for a longer shelf life and improved physiological compatibility.
Implementation Method 1
Nonenzymatic spontaneous hydrolysis of aqueous atropine yields tropine and tropic acid
Implementation Method 2
viscosity modifiers like hydroxyethyl cellulose, which maintains atropine stability
Data Source
AI summary
The inventive subject matter is directed to compositions and methods for sterile and storage stable low-dose atropine formulations with improved stability. Most preferably, the compositions presented herein are substantially preservative free and exhibit less than 0.35% tropic acid from degradation of atropine. Advantageously, contemplated formulations are also substantially free of preservatives.